RS Investment Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

RS Investment Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q2	$978K	Sell	20,000 -390,548	-95%	-$25.3M	0.01%	327
2016 Q1	$26M	Buy	410,548 +26,325	+7%	+$1.72M	0.26%	137
2015 Q4	$43.1M	Sell	384,223 -5,950	-2%	-$595K	0.39%	94
2015 Q3	$37.6M	Buy	390,173 +41,060	+12%	+$4.7M	0.34%	112
2015 Q2	$35.7M	Buy	349,113 +23,952	+7%	+$1.86M	0.31%	124
2015 Q1	$20.2M	Sell	325,161 -33,217	-9%	-$1.85M	0.18%	184
2014 Q4	$15.7M	Buy	358,378 +147,937	+70%	+$6.78M	0.14%	219
2014 Q3	$11.9M	Buy	210,441 +4,900	+2%	+$247K	0.11%	220
2014 Q2	$9.23M	Buy	205,541 +26,441	+15%	+$1.09M	0.08%	237
2014 Q1	$8.76M	Buy	+179,100	New	+$9.22M	0.05%	236

Other funds holding RARE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

CWAM

Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return

RS Investment Management's RARE Position: Q2 2016 in Review

RS Investment Management reduced its Ultragenyx Pharmaceutical (RARE) stake by 95% in Q2 2016, selling an estimated $25.3M and leaving 20,000 shares worth $978K. The position accounts for 0.01% of the portfolio, ranked #327.

RS Investment Management first reported a position in RARE in Q1 2014 and has held it in 10 quarters since. The position peaked at $43.1M in Q4 2015. 162 funds tracked by Wall St. Rank hold RARE as of Q2 2016.

RS Investment Management held 20,000 shares of Ultragenyx Pharmaceutical worth $978K as of Q2 2016.
RS Investment Management sold 390,548 Ultragenyx Pharmaceutical shares in Q2 2016, an estimated $25.3M.
Ultragenyx Pharmaceutical made up 0.01% of RS Investment Management's portfolio in Q2 2016, its #327 holding.
RS Investment Management first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 10 quarters since.
RS Investment Management's Ultragenyx Pharmaceutical position peaked at $43.1M in Q4 2015.
162 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2016.

Based on RS Investment Management's 13F filing for Q2 2016, filed 26 Jul 2016.